Brincker H, Bentzen S M
Department of Oncology and Hematology, Odense University Hospital, Denmark.
Radiother Oncol. 1994 Mar;30(3):227-30. doi: 10.1016/0167-8140(94)90462-6.
A re-analysis of all available dose-response data on Hodgkin's disease, compiled recently by Vijayakumar and Myrianthopoulos (Vijayakumar, S. and Myrianthopoulos, L.C. An updated dose-response analysis in Hodgkin's disease. Radiother. Oncol. 24: 1-13, 1992), fails to demonstrate any dose-response relationship at doses higher than 32.5 Gy. Thus, in contrast with these authors, we find no evidence that local control will be improved by radiation doses of more than 32.5 Gy. A review of the available data on the time-dose relationship in Hodgkin's disease indicates that overall treatment time, at least up until 7 weeks, is not of major importance. Further, there is some indication that the sensitivity to changes in dose per fraction is low. This allows the fraction size to be selected from considerations of the level of late treatment related morbidity.
维贾亚库马尔和米里安托普洛斯最近汇编了关于霍奇金病所有可用的剂量反应数据并进行了重新分析（维贾亚库马尔，S. 和米里安托普洛斯，L.C. 《霍奇金病最新剂量反应分析》。《放射肿瘤学》24: 1 - 13, 1992），结果未能显示出在高于32.5戈瑞的剂量下存在任何剂量反应关系。因此，与这些作者的观点相反，我们没有发现证据表明超过32.5戈瑞的放射剂量会改善局部控制。对霍奇金病时间 - 剂量关系的现有数据进行回顾表明，至少在7周之前，总的治疗时间并非至关重要。此外，有迹象表明对每次分割剂量变化的敏感性较低。这使得可以根据后期治疗相关发病率的水平来选择分割剂量大小。
